| Research article - (2026)25, 350 - 370 DOI: https://doi.org/10.52082/jssm.2026.350 |
| Acute Impact of Cold Compression Therapy Across Diverse Age Groups and Physical Conditioning Status: A Randomized Crossover Study |
Robert Trybulski1,2, Adrian Kużdżał3, Gracjan Olaniszyn1,4, Ana Filipa Silva5, Filipe Manuel Clemente6,7,8, , Wang Hsing-Kuo9,10 |
| Key words: Cryotherapy, Compression, Muscle Fatigue, Recovery of Function, Sports Medicine |
| Key Points |
|
|
|
| Patient and public involvement |
Patients or members of the public were not involved in the design, conduct, reporting, or dissemination plans of this study. The selection of study populations (elite mixed martial arts athletes, healthy young adults, and healthy adults over 50 years) was based solely on methodological and scientific considerations described in the Introduction. |
| Study design |
This investigation was conducted as a multicenter, randomized, participant- and assessor-blinded, sham-controlled, two-period crossover clinical trial with a superiority framework. Three independent research centers in Poland participated: The Provita Medical Center in Żory, responsible for elite mixed martial arts athletes; the Upper Silesian Academy in Katowice, responsible for young adults; and the Medical Center in Racibórz, responsible for adults over 50 years of age. Each participant completed two study periods, separated by a washout interval of 14 days to minimize carryover effects. In one period, participants received the active intervention consisting of pneumatic cold-compression system therapy, while in the other period they received the sham comparator, with the sequence randomized in a 1:1 ratio. At the beginning of each study period, participants performed a standardized fatigue protocol based on the Nordic Hamstring Exercise to volitional exhaustion, after which the allocated intervention was initiated. The intervention phase comprised six treatment sessions, scheduled twice daily in the morning between 8:00 and 11:00 and in the evening between 17:00 and 20:00, over the course of three consecutive days. Outcome assessments were performed at five predefined time points. Baseline values were recorded before the fatigue protocol (T0), immediately after the completion of the fatigue protocol (T1), immediately following the first intervention session (T2), twenty-four hours after the fatigue protocol (T3), and forty-eight hours after the fatigue protocol (T4). This structure allowed the evaluation of both acute and short-term recovery dynamics, while ensuring that each participant served as their own control, thereby improving statistical efficiency and minimizing the influence of interindividual variability. |
| Trial setting, registration, and ethics |
The trial was conducted between June and September 2025 under controlled laboratory conditions, with room temperature maintained between 20-22 °C and relative humidity kept stable across centers. The study was prospectively registered in the International Standard Randomised Controlled Trial Number (ISRCTN) registry under the number ISRCTN49499065( |
| Eligibility criteria |
Eligibility criteria were defined separately for each study population. For the elite mixed martial arts (MMA) group, inclusion required a minimum of 5 years of continuous training with at least 5 weekly sessions, participation in at least three professional fights, and classification within grade I or II according to the McKay framework (McKay et al., Centers were required to have access to standardized laboratory equipment for biomechanical and physiological measurements and to controlled environmental testing conditions. All interventionists received standardized training in the use of the pneumatic cold-compression system and in delivering sham protocols. Importantly, personnel responsible for interventions were distinct from those conducting outcome assessments, to preserve blinding. |
| Intervention and Comparator Experimental intervention (pneumatic cold compression therapy- CC) |
Cold compression was delivered using a multi-modality pneumatic cold-compression unit (Med4 Elite, Game Ready/Avanos Medical, USA). The Med4 Elite is an AC-powered, software-controlled device designed for professional clinical use, providing iceless cold therapy, thermotherapy, rapid contrast (alternating heat and cold), and intermittent pneumatic compression for up to two patients simultaneously. Treatment parameters (therapy mode, total treatment time, and minimum/maximum treatment temperature) are set on an integrated touchscreen in either °C or °F, and maintained by an internal refrigeration and heat-exchange system rather than ice. The system delivers cold and compression through dual-chamber “Active Temperature Exchange” (ATX®) wraps, which incorporate separate channels for circulating fluid and air and are anatomically contoured to provide circumferential coverage of the limb. Intermittent pneumatic compression is generated within the air chamber at pre-set levels (low, medium-low, medium, high), corresponding to approximate peak cuff pressures from about 5 up to 75 mmHg in cold-therapy and compression-only modes. In the present study, only the cold-therapy mode combined with intermittent pneumatic compression was used, with the cold module set to 3 °C and the compression level set to “high” (nominal peak pressure 75 mmHg), applied via full-thigh wraps to the exercised limb for each treatment session. Participants were positioned supine with both thighs enveloped by wraps ensuring full sleeve-to-skin contact (no clothing between wrap and skin). The controller was set to cold at 3 °C and intermittent compression targeting 75 mmHg (high mode) for 10 min per session, delivered twice daily (08:00-11:00 and 17:00-20:00) over three consecutive days (total 6 sessions, 60 min cumulative exposure). Within each 10-min exposure, the device’s automated duty cycle applied rhythmic inflation/deflation to maintain the high-mode pressure profile (engineer-fixed cycle timing), providing a dynamic mechanothermal stimulus while participants remained relaxed. The choice of 3 °C with high-mode compression is aligned with contemporary sport-science trials using pneumatic cold-compression system that explicitly applied 3 °C and 75 mmHg and reported acute improvements in perfusion and muscle mechanical properties, supporting these settings as therapeutically active for skeletal muscle recovery (Trybulski et al., In hamstring-focused work with pneumatic cold-compression system, high intermittent pressure spanning 5-75 mmHg has been used together with a target cooling of ~10 °C after fatiguing exercise, further validating the upper end of the compression range for lower-limb musculature in athletic cohorts (Alexander et al., |
| Comparator (sham cryo-compression) |
Sham sessions matched the active protocol for participant position, wrap type, session timing, and total exposure but used milder settings designed to mimic sensation without producing meaningful mechanophysiological change: controller temperature 15 °C and compression 15 mmHg in intermittent mode. These low-cooling/low-pressure parameters are consistent with sham conditions used in pneumatic cold-compression system trials (e.g., sham temp 15-36 °C with 15-25 mmHg), which have been shown to preserve blinding while minimizing physiological effects relative to active dosing (Trybulski et al., |
| Treatment delivery, fidelity and safety considerations |
At each site, interventions (active and sham) were delivered by physiotherapists with ≥5 years of clinical experience who completed centralized hands-on training with the Med4 Elite and trial SOPs before enrollment began; treating therapists were not involved in outcome assessment. Session-level fidelity checklists documented device model/serial number, wrap size, side(s) treated, set temperature, compression mode, start/stop times, and any deviations; device parameters were verified prior to each session. The controller’s compression modes follow manufacturer-defined pressure ranges (e.g., high = 5-75 mmHg) and automated inflation/deflation cycles, ensuring reproducible dosing across centers; these specifications were used to standardize settings and were not user-editable beyond the chosen mode. Prior to each session, skin integrity and sensation were checked; sessions were discontinued for excessive cold pain, numbness, abnormal skin changes, or cardiovascular instability (Khoshnevis et al., |
| Fatigue protocol |
To induce a standardized and reproducible state of hamstring fatigue, participants performed the Nordic Hamstring Exercise (NHE) on a dedicated kneeling apparatus with the ankles secured under padded rollers, the hips held in full extension, the trunk aligned with the thighs, and the arms crossed on the chest; from this position, they leaned forward under eccentric control until they could no longer resist the descent and then used their hands to prevent a fall, a technique consistent with canonical descriptions of the NHE in training and research (Mjølsnes et al., The protocol comprised three sets performed to volitional exhaustion with two minutes of seated rest between sets, and exhaustion was operationalized as the inability to maintain a controlled eccentric lowering for two consecutive repetitions despite standardized encouragement from the assessor, which reflects common practice in experiments using repeated NHE exposures to elicit acute fatigue (Magdalena et al., One week before experimental testing, all participants completed a familiarization session in which they received standardized instruction and performed supervised practice repetitions to minimize learning effects and ensure consistent technique during data collection, an approach aligned with reliability work showing improved measurement quality when NHE execution is standardized and rehearsed before testing (Lee et al., |
| Outcomes |
All outcome assessments were scheduled around this stimulus at five predefined timepoints to capture both the immediate effects of fatigue and short-term recovery: baseline before NHE (T0), immediately post-NHE (T1), immediately after the first intervention session (T2), twenty-four hours post-NHE (T3), and forty-eight hours post-NHE (T4), with assessors trained to monitor technique and discontinue the set if hip flexion, compensatory trunk movements, or undue discomfort compromised safe execution, consistent with safety practices in eccentric hamstring testing. |
| Muscle function |
The primary outcome was maximal voluntary contraction of the knee flexors (MVC), recorded bilaterally with a handheld dynamometer (Kinvent K-Force) while participants lay prone with the hip extended and knee at 30° flexion; two five-second maximal isometric trials were performed per leg with 60 seconds of rest between attempts, and the highest value was retained for analysis. MVC was expressed in Newtons (N). Handheld dynamometry provides reliable and valid estimates of knee flexor strength in healthy populations and has been recommended for both clinical and research applications (Mentiplay et al., |
| Metabolic response |
Systemic metabolic recovery was quantified by capillary blood lactate concentration (mmol·L-1) using a portable analyzer (Lactate Scout+, EKF Diagnostics, Leipzig, Germany), which has been validated for accuracy and reliability in exercise physiology research (Tanner et al., |
| Microvascular perfusion |
Local circulatory function was assessed by laser Doppler flowmetry (PeriFlux 6000, Perimed, Sweden). The probe was affixed over the biceps femoris at a standardized midpoint between the ischial tuberosity and fibular head. Following a five-minute resting familiarization period in the testing position, perfusion was recorded continuously for two minutes at each timepoint. The outcome was expressed as mean perfusion units (PU). Laser Doppler flowmetry is an established technique for quantifying human microvascular function with reproducible results (Roustit and Cracowski, |
| Muscle mechanical properties |
Hamstring muscle stiffness was measured using the MyotonPRO (Myoton AS, Estonia). The device probe was applied perpendicularly to the biceps femoris, and three consecutive mechanical impulses were delivered at one-second intervals. The mean of the three readings was extracted for analysis. Stiffness was expressed in Newtons per meter (N/m). Myotonometry has been validated as a reliable method for characterizing muscle viscoelastic properties (Chen et al., |
| Sensory response |
Pain sensitivity was measured by the pressure pain threshold (PPT) using a digital algometer (Wagner Instruments, Greenwich, CT, USA). The probe was applied to the biceps femoris with steadily increasing force until the participant reported the first sensation of discomfort, and three trials were averaged. PPT was expressed in kilopascals (kPa). Digital pressure algometry has been shown to provide reliable PPT measures for musculoskeletal tissues (Park et al., |
| Subjective perception |
Recovery perceptions were assessed with the Total Quality of Recovery (TQR) scale, which ranges from 6 (very poor recovery) to 20 (very good recovery). Perceived exertion was simultaneously measured with the Borg CR10 scale, which ranges from 0 (no exertion) to 10 (maximal exertion). Both were administered once at each timepoint without repetition, and the scores were recorded as absolute values. The TQR scale has been validated as a monitoring tool for athlete recovery (Kenttä and Hassmén, |
| Harms |
Harms were prespecified as excessive pain, abnormal skin reactions, cold-induced numbness or paresthesia, or cardiovascular instability. The skin was inspected immediately before and after each cryo-compression session, and participants were systematically queried for unusual sensations at each timepoint. |
| Sample size |
The a priori sample size calculation focused on the primary endpoint, defined as the within-participant difference between CC and Sham in change of hamstring maximal voluntary contraction (MVC) from baseline to 48 h after the fatiguing task (ΔMVC T4 - T0) in the two-period, two-sequence crossover. For planning, we approximated the analysis by a paired t-test on the within-participant treatment difference at T4, which is a standard approach for crossover trials with a single primary post-treatment time point. Published crossover studies of lower-limb cryo-compression (Julious et al., Due to pragmatic considerations related to multicenter logistics and recruitment timelines, enrollment was capped at 80 participants (40 elite MMA athletes, 20 young adults, 20 older adults), all of whom completed both periods. With this achieved sample, the observed within-participant effect size for ΔMVC at T4 (dz = 1.0) yielded post hoc power >99% for the primary comparison at α = 0.05, indicating that the study remained well powered for the effect actually observed. |
| Randomization |
The random allocation sequence was generated prior to recruitment by an independent statistician not otherwise involved in participant enrollment, intervention delivery, or outcome assessment. Randomisation was computer-based, using a reproducible pseudo-random number generator (R statistical software, version 4.3). The trial used stratified block randomisation with variable block sizes of 4 and 6 to ensure balanced allocation within each study population (elite mixed martial arts athletes, young adults, and adults over 50 years) and by sex. Participants were randomized in a 1:1 ratio to one of two treatment sequences: (i) pneumatic cold-compression system followed by sham, or (ii) sham followed by pneumatic cold-compression system. Stratification minimized the risk of imbalances in demographic and training-related characteristics across the crossover sequences. Allocation concealment was maintained using sequentially numbered, opaque, sealed envelopes prepared at the coordinating center. Envelopes were identical in appearance, tamper-proof, and opened only after baseline testing and enrollment were complete. The envelopes contained the treatment sequence assignment for each participant and were kept in a secure location accessible only to the local trial coordinator. Neither participants nor outcome assessors had access to the allocation sequence at any time. |
| Blinding |
Outcome assessors, data-entry personnel, and statisticians were blinded to treatment allocation throughout the study. Because the active and sham interventions were delivered using the same device, wrap, positioning, session timing, and therapist contact, participant blinding was attempted. However, the active condition (3 °C with high intermittent compression up to 75 mmHg) and the sham condition (15 °C with minimal intermittent compression of 15 mmHg) differed in sensory intensity, and no formal blinding assessment was performed. Therefore, the success of participant blinding could not be verified and should be considered uncertain. Only the physiotherapists delivering the intervention were aware of allocation, and they had no role in recruitment, randomisation, or outcome assessment. |
| Statistical analysis |
Continuous outcomes (maximal voluntary contraction [MVC], muscle stiffness, microvascular perfusion, pressure pain threshold [PPT], and blood lactate) were analyzed using three-way mixed ANOVA, with Population (MMA athletes, young adults, and older adults) as the between-subject factor and Condition (CC vs Sham) and Time (T0 - T4) as within-subject factors. Descriptive data are presented as mean ± SD. For each model, residuals were inspected graphically (Q-Q plots, histograms, and residuals-versus-fitted plots), Shapiro-Wilk tests were used to assess approximate normality, and sphericity for repeated factors was examined using Mauchly’s test; when sphericity was violated, Greenhouse–Geisser corrections were applied. Omnibus effects are reported as F statistics with corrected degrees of freedom where appropriate, associated p values, and partial eta squared (ηp2). Significant main effects and interaction terms were explored using Bonferroni-adjusted post hoc comparisons. To provide the detailed contrasts reported in the |
|
|
| Participant flow and recruitment |
Among the 120 individuals screened/recruited, 80 were randomized into the crossover trial, with equal distribution to the two intervention sequences: Sequence A (CC to Sham, n = 40) and Sequence B (Sham to CC, n = 40). All participants received the intended interventions in both periods and were included in the analyses of the primary outcome. No participants were lost to follow-up, discontinued the interventions, or were excluded from the final analyses. Thus, the per-protocol and intention-to-treat samples were identical. The full trajectory of participants through screening, allocation, and analysis is displayed in the CONSORT flow diagram ( Of the randomized participants, 40 were elite mixed martial arts (MMA) athletes, 20 were healthy young adults, and 20 were healthy, physically active older adults. Within each subgroup, allocation was balanced between the two crossover sequences (MMA: 20/20; Young: 10/10; Older: 10/10). All participants completed both intervention phases and were analysed for the primary outcome, resulting in complete paired data across conditions for MVC at baseline and 48 h. There were no losses, withdrawals, or exclusions after randomisation. All randomized participants were retained through both intervention arms, with no adverse events or protocol deviations reported that required exclusion. At baseline, MMA athletes (n = 40) had a mean age of 27.2 ± 3.5 years, height of 179.2 ± 7.6 cm, weight of 76.3 ± 10.2 kg, body mass index (BMI) of 23.7 ± 2.6 kg/m2, and training experience of 11.0 ± 2.8 years. The healthy young adults (n = 20) had a mean age of 21.8 ± 1.6 years, height of 171.3 ± 8.0 cm, weight of 68.0 ± 10.6 kg, BMI of 23.1 ± 2.4 kg/m2, and training experience of 2.5 ± 1.4 years. The healthy, physically active older adults (n = 20) presented with a mean age of 55.6 ± 3.8 years, height of 171.8 ± 7.8 cm, weight of 77.3 ± 12.0 kg, BMI of 26.1 ± 3.2 kg/m2, and training experience of 7.3 ± 2.6 years. For the overall cohort of 80 participants, the mean age was 33.0 ± 13.7 years, height 175.4 ± 8.6 cm, weight 74.5 ± 11.3 kg, BMI 24.2 ± 2.9 kg/m2, and training experience 8.0 ± 4.3 years. Because of the large amount of statistical data, descriptive tables for all outcomes, conditions, and populations are provided in Supplementary Material 1. |
| Fatigue induction and recovery status |
The Nordic hamstring protocol induced a marked immediate reduction in maximal voluntary contraction (MVC) in all three populations ( |
| Primary outcome: maximal voluntary contraction |
MVC trajectories are shown in |
| Primary outcome: maximal voluntary contraction |
MVC trajectories are shown in |
| Secondary Outcomes Muscle stiffness |
Muscle stiffness trajectories are presented in |
| Microvascular perfusion |
Perfusion trajectories are shown in |
| Pressure pain threshold |
Pressure pain threshold (PPT) trajectories are shown in |
| Blood lactate |
Lactate trajectories are shown in |
| Perceived recovery |
Perceived recovery, assessed with the Total Quality of Recovery (TQR) scale, is summarized in |
| Perceived exertion and harms |
Borg CR10 ratings recorded immediately after the fatigue protocol are shown in |
|
|
Our results suggest that CC accelerated recovery following a standardized hamstring fatiguing task across three distinct populations. Relative to Sham, CC produced faster and larger restoration of MVC at 48 h (T4), lower hamstring stiffness during recovery, higher microvascular perfusion from immediately post-intervention through 48 h (T2 - T4), greater PPT, earlier reduction in blood lactate at T2, and higher TQR. All randomized participants completed both arms without adverse events, and effects were consistent across subgroups, supporting the robustness and generalizability of the treatment effect. An important interpretive point is that T2 was assessed immediately after the first intervention session and therefore does not represent recovery in isolation. At this timepoint, the observed differences may partly reflect acute physiological responses to cold and compression, including transient hemodynamic, sensory, and mechanical effects, rather than a sustained recovery benefit per se. Accordingly, T2 findings should be interpreted as an immediate post-intervention response, whereas T3 and T4 provide a more informative indication of the recovery trajectory over time. CC substantially improved MVC recovery by 48 h, but the onset varied since MMA athletes and students showed earlier recovery (T2), whereas older adults exhibited delayed recovery (T3). The superiority of CC over Sham for MVC should be interpreted as an improvement in the recovery trajectory rather than full restoration of neuromuscular function. This distinction was especially important in older adults, in whom MVC under CC remained at only 69.0% of baseline at 48 h, indicating a persistent residual strength deficit despite the significant between-condition benefit. Generally, the results on CC and MVC are directionally consistent with contemporary meta-analytic evidence that cold-water immersion (a proxy for the cooling component of CC) can aid short-term recovery of strength following strenuous exercise (Moore et al., Hamstring stiffness rose after the fatiguing task and remained consistently lower under CC than Sham from T2 through T4, indicating faster mechanical recovery with cold-compression. However, stiffness did not return to baseline by 48 h in either condition. Accordingly, the present results support accelerated or partial recovery rather than complete mechanical restoration within the observation period. This should be interpreted in light of the relatively short 48 h follow-up, which may not have been sufficient to capture the full time course of recovery. Post-exercise increases in passive muscle stiffness over 24-96 h are well documented with myotonometry (Kong et al., CC yielded higher perfusion units from T2 - T4 than Sham, which is plausible given that compression acutely increases limb blood flow during and after exercise (Zuj et al., CC increased pressure pain thresholds, again with earlier improvements in MMA athletes and young adults and delayed improvements in older adults, consistent with both cryotherapy-induced hypoalgesia and compression-related modulation of soreness. General improvements after CC are consistent with cryotherapy-induced hypoalgesia (Algafly and George, These findings suggest that the PPT improvements under CC are more likely attributable to the combined cryo-compression stimulus than to compression alone (Draper, Several limitations warrant consideration. This study has some limitations. First, the achieved sample (n = 80) was smaller than the original a priori target (n = 117), and the subgroup allocation was unequal (40 MMA athletes, 20 young adults, and 20 older adults). This reflected feasibility constraints, including multicenter logistics, the predefined recruitment window, and the limited availability of elite MMA athletes, who represented the population of greatest applied interest in this study. Although the crossover design increased statistical efficiency by allowing within-participant comparisons and all enrolled participants completed both periods, the reduced and unbalanced sample still limits precision, particularly for between-population comparisons. Therefore, subgroup findings should be interpreted as exploratory and confirmed in larger, prospectively powered studies with more balanced allocation. Moreover, while myotonometry provided a valid and reliable index of muscle stiffness, this approach does not capture deeper muscle or tendon adaptations, and we did not employ shear-wave elastography or MRI to complement mechanical data. Also, our trial design did not include direct biochemical markers of inflammation (e.g., cytokines) or imaging of intramuscular blood flow, restricting mechanistic inference. Third, we standardized the device set-points (3 °C cold mode, high intermittent compression nominally targeting 75 mmHg) but did not directly measure individual skin or intramuscular temperatures, nor did we log real-time cuff pressures at the limb. As a result, we cannot quantify the actual mechanothermal dose delivered at the tissue level or examine inter-individual variability in temperature or pressure responses. This limitation constrains interpretation and means that our findings should be interpreted as effects of a pragmatic device protocol rather than of a precisely characterized thermal and mechanical dose. Finally, the intervention was delivered with a single commercial device under a fixed protocol; whether alternative cooling temperatures, pressures, or application schedules yield similar results remains to be clarified. Despite the limitations, our findings suggest that CC can be integrated as a safe and effective recovery modality across populations spanning elite athletes to older active adults. In high-performance sport, CC may facilitate more rapid restoration of strength, muscle mechanics, and pain thresholds, supporting readiness for subsequent training or competition. In clinical or rehabilitation settings, particularly in older populations, cryo-compression may provide a non-pharmacological strategy to enhance comfort, vascular supply, and perceived recovery after strenuous activity or therapy. Importantly, the protocol we used (cooling at 3 °C with 75 mmHg intermittent compression for 10 minutes, twice daily across 3 days) was both feasible and well tolerated, offering a replicable template for practitioners. The convergence of physiological, perceptual, and functional benefits emphasizes the value of CC as an adjunct recovery tool that can complement, but not replace, other strategies such as active recovery, nutrition, and sleep. However, CC improved the short-term recovery trajectory after eccentric exercise, although complete recovery of muscle stiffness was not observed within 48 h. |
|
|
This multicenter, randomized, sham-controlled, crossover trial demonstrated that CC accelerates recovery following hamstring fatigue across elite mixed martial arts athletes, healthy young adults, and physically active older adults. Compared with Sham, CC enhanced restoration of maximal voluntary contraction, reduced post-exercise muscle stiffness, improved microvascular perfusion, elevated pressure pain thresholds, facilitated early lactate clearance, and increased subjective recovery. While benefits were observed in all groups, their onset differed: athletes and young adults showed earlier gains, whereas older adults responded later but achieved comparable improvements by 48 h. These findings underscore both the broad applicability of CC and the influence of age and training status on recovery dynamics. Further research should refine dosing parameters, integrate mechanistic biomarkers, and benchmark CC against other recovery modalities. |
| ACKNOWLEDGEMENTS |
The authors have no funding to disclose. The authors declare no conflicts of interest. The datasets generated during the current study are not publicly available but are available from the corresponding author upon reasonable request. All experimental procedures were conducted in compliance with the relevant legal and ethical standards of the country where the study was carried out. The authors declare that no Generative AI or AI-assisted technologies were used in the writing of this manuscript. |
| AUTHOR BIOGRAPHY |
|
| REFERENCES |
|